Download PDF
Laryngorhinootologie 2022; 101(01): 22-34
DOI: 10.1055/a-1351-0417
Übersicht

Kurative Radiochemotherapie von Kopf-Hals-Tumoren

The role of chemoradiotherapy in curative treatment of head and neck cancer
Christine Langer 
1   HNO, Universitätsklinikum Gießen und Marburg Standort Gießen, Klinik für Hals-Nasen-Ohrenheilkunde, Kopf-Halschirurgie und plastische Operationen, Gießen, Germany
,
Claus Wittekindt
2   HNO-Klinik, Klinikum Dortmund gGmbH, Dortmund, Germany
,
Alexandra Désirée Jensen
3   Klinik für Strahlentherapie, Universitätsklinikum Gießen und Marburg GmbH Standort Gießen, Gießen, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Radio- und Chemotherapie stellen sowohl als definitiver Therapieansatz als auch im adjuvanten Setting wesentliche Bestandteile der Behandlung von malignen Kopf-Hals-Tumoren dar. Der Behandlungserfolg ist hier wesentlich abhängig von Auswahl und Dosierung der verwendeten Substanzen sowie vom spezifischen radiotherapeutischen Setting in Bezug auf Fraktionierung, Therapiegesamtdauer und Bestrahlungstechnik.

Hinzu kommen Untersuchungen zur immunologisch basierten Therapie und strahlentherapeutischen Modifikation durch Evaluation der Partikeltherapie innerhalb oder additiv zu etablierten Behandlungskonzepten. Die Therapie HPV-induzierter Tumoren stellt aufgrund der differenten Tumorbiologie und des damit verbundenen verbesserten Gesamtüberlebens eine weitere aktuell untersuchte therapeutische Herausforderung dar.

Abstract

Radiotherapy and chemotherapy are integral parts of definitive and adjuvant therapy in the treatment of head and neck squamous cell carcinoma (HNSCC). The outcome of therapy is essentially dependent on selection and dosage of chemotherapeutical substances and on the other hand on the radiotherapeutical setting concerning fractionation, time of therapy and technical aspects. Immunotherapeutical substances have an increasing role in the therapy of HNSCC as well as particle therapy is investigated as part of radiotherapy in actual studies. Further challenges relate to treatment of HPV-induced tumors with regard to their differences in tumor biology and consecutively better prognosis.

Schlüsselwörter

HNSCC - Radiochemotherapie - Radioimmuntherapie - Fraktionierung - Deintensivierung

Key words

HNSCC - chemoradiation - radiochemotherapy - radio-immunotherapy - fractionation


Publication History

Received: 13 November 2020

Accepted: 07 January 2021

Article published online:
27 January 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Forastiere AA, Goepfert H, Maor M. et al Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. New England Journal of Medicine 2003; 349: 22 . doi:10.1056/nejmoa031317
    CrossrefPubMedGoogle Scholar
  • 2 Megwalu UC, Sikora AG. Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngology – Head and Neck Surgery 2014; 140: 9 . doi:10.1001/jamaoto.2014.1671
    CrossrefPubMedGoogle Scholar
  • 3 Mornex F, Pavy JJ, Denekamp J. et al Scoring system of late effects of radiations on normal tissues: the SOMA-LENT scale. Cancer radiothérapie: journal de la Société française de radiothérapie oncologique 1997; 1: 6
    PubMedGoogle Scholar
  • 4 Group DS. DÖSAK Study Group. Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis, NCT00964977e. Accessed 2020 July 7 https://clinicaltrials.gov/ct2/show/NCT00964977?term=NCT00964977&draw=2&rank=1
    PubMedGoogle Scholar
  • 5 Leitlinienprogramm NN. AWMF. Mundhöhlenkarzinom. Published 2012. Accessed July 7, 2020. https://www.leitlinienprogramm-onkologie.de/leitlinien/mundhoehlenkarzinom/
    PubMedGoogle Scholar
  • 6 Leitlinienprogramm NN. AWMF. LarynxKarzinom. Published online 2019. https://www.leitlinienprogramm-onkologie.de/leitlinien/larynxkarzinom/
    PubMedGoogle Scholar
  • 7 Cooper JS, Pajak TF, Forastiere AA. et al Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine 2004; 350: 19 . doi:10.1056/nejmoa032646
    CrossrefPubMedGoogle Scholar
  • 8 Cooper JS, Zhang Q, Pajak TF. et al Long-term follow-up of the RTOG 9501/intergroup phase III trial: Postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology Biology Physics 2012; 84: 5 . doi:10.1016/j.ijrobp.2012.05.008
    CrossrefPubMedGoogle Scholar
  • 9 Bernier J, Cooper JS, Pajak TF. et al Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head and Neck 2005; 27: 10 . doi:10.1002/hed.20279
    CrossrefPubMedGoogle Scholar
  • 10 Evans M, Knott S, Hurt C. et al PATHOS: A phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer. Journal of Clinical Oncology 2018; 36 (Suppl. 05) DOI: 10.1200/jco.2018.36.15_suppl.tps6097.
    CrossrefPubMedGoogle Scholar
  • 11 van der Vorst MJDL, Neefjes ECW, Toffoli EC. et al Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer 2019; 19: 1 . doi:10.1186/s12885-019-6233-9
    CrossrefPubMedGoogle Scholar
  • 12 Noronha V, Joshi A, Patil VM. et al Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. Journal of Clinical Oncology 2017; 35 (Suppl. 15) DOI: 10.1200/jco.2017.35.15_suppl.6007.
    CrossrefPubMedGoogle Scholar
  • 13 Bachaud JM, Cohen-Jonathan E, Alzieu C. et al Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. International Journal of Radiation Oncology Biology Physics 1996; 36: 5 . doi:10.1016/S0360-3016(96)00430-0
    CrossrefPubMedGoogle Scholar
  • 14 Kunieda F, Kiyota N, Tahara M. et al Randomized phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck: Japan Clinical Oncology Group study (JCOG1008). Japanese Journal of Clinical Oncology 2014; 44: 8 . doi:10.1093/jjco/hyu067
    CrossrefPubMedGoogle Scholar
  • 15 Lee JY, Sun JM, Oh DR. et al Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiotherapy and Oncology 2016; 118: 2 . doi:10.1016/j.radonc.2015.11.030
    PubMedGoogle Scholar
  • 16 Lee SY, Choi YS, Song IC. et al Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis. Medicine (United States) 2018; 97: 21 . doi:10.1097/MD.0000000000010778
    PubMedGoogle Scholar
  • 17 Hermann RM, Christiansen H. Carboplatin verbessert nicht die Wirksamkeit der adjuvanten Radiotherapie bei fortgeschrittenen kutanen Plattenepithelkarzinomen der Kopf-Hals-Region. Carboplatin does not increase the effectiveness of adjuvant radiotherapy in advanced cutaneous squamous cell carcinoma of the head and neck region. Strahlentherapie und Onkologie 2018; 194: 12 . doi:10.1007/s00066-018-1375-2
    CrossrefPubMedGoogle Scholar
  • 18 Rades D, Ulbricht T, Hakim SG. et al Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity. Strahlentherapie und Onkologie 2012; 188: 1 . doi:10.1007/s00066-011-0005-z
    CrossrefPubMedGoogle Scholar
  • 19 Harrington K, Temam S, Mehanna H. et al Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: A phase III, randomized, double-blind, placebo-controlled study. Journal of Clinical Oncology 2015; 33: 35 . doi:10.1200/JCO.2015.61.4370
    CrossrefPubMedGoogle Scholar
  • 20 Araki D, Redman MW, Martins R. et al Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience. Head and Neck 2016; 38: 9 . doi:10.1002/hed.24437
    CrossrefPubMedGoogle Scholar
  • 21 Ferris RL, Geiger JL, Trivedi S. et al Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer. Annals of oncology: official journal of the European Society for Medical Oncology 2016; 27: 12 . doi:10.1093/annonc/mdw428
    CrossrefPubMedGoogle Scholar
  • 22 Harrington K, Berrier A, Robinson M. et al Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease. European Journal of Cancer 2013; 49: 7 . doi:10.1016/j.ejca.2012.11.023
    CrossrefPubMedGoogle Scholar
  • 23 Harrington KJ, El-Hariry IA, Holford CS. et al Phase i study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 2009; 27: 7 . doi:10.1200/JCO.2008.17.5349
    CrossrefPubMedGoogle Scholar
  • 24 Margalit DN, Haddad RI, Tishler RB. et al A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics 2019; 105: 1 . doi:10.1016/j.ijrobp.2019.04.034
    PubMedGoogle Scholar
  • 25 Network) NN (National CC. NCCN Practice Guideline: Head and Neck Cancer. 2020;(2). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
    PubMedGoogle Scholar
  • 26 Graboyes EM, Garrett-Mayer E, Ellis MA. et al Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. Cancer 2017; 123: 24 . doi:10.1002/cncr.30939
    CrossrefPubMedGoogle Scholar
  • 27 Chao HH, Schonewolf CA, Tan EX. et al The impact of treatment package time on locoregional control for HPV+ oropharyngeal squamous cell carcinoma treated with surgery and postoperative (chemo)radiation. Head and Neck 2019; 41: 11 . doi:10.1002/hed.25914
    PubMedGoogle Scholar
  • 28 Suzuki H, Terada H, Hanai N. et al Treatment package time predicts cancer-specific survival and distant metastasis in laryngeal cancer. Oncology Letters 2019; 17: 1 . doi:10.3892/ol.2018.9664
    PubMedGoogle Scholar
  • 29 Lee NCJ, Kelly JR, An Y. et al Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma. Cancer 2019; 125: 12 . doi:10.1002/cncr.32001
    CrossrefPubMedGoogle Scholar
  • 30 Tumati V, Hoang L, Sumer BD. et al Association between treatment delays and oncologic outcome in patients treated with surgery and radiotherapy for head and neck cancer. Head and Neck 2019; 41: 2 . doi:10.1002/hed.25457
    CrossrefPubMedGoogle Scholar
  • 31 Amini A, Stokes WA, Jones BL. et al Postoperative radiation performed at the same surgical facility associated with improved overall survival in oral cavity squamous cell carcinoma. Head and Neck 2019; 41: 7 . doi:10.1002/hed.25697
    CrossrefPubMedGoogle Scholar
  • 32 Teng MS, Gupta V. Timely Adjuvant Postoperative Radiotherapy: Racing to a PORT in the Storm. JAMA Otolaryngology – Head and Neck Surgery 2018; 144: 12 . doi:10.1001/jamaoto.2018.2266
    PubMedGoogle Scholar
  • 33 Blanchard P, Baujat B, Holostenco V. et al Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiotherapy and Oncology 2011; 100: 1 . doi:10.1016/j.radonc.2011.05.036
    CrossrefPubMedGoogle Scholar
  • 34 Pignon JP, Bourhis J, Domenge C. et al Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta analysis of chemotherapy on head and neck cancer. Cancer/Radiothérapie 2001; 5: 2 . doi:10.1016/s1278-3218(00)00073-1
    CrossrefPubMedGoogle Scholar
  • 35 Pignon JP, le Maître A, Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update. International Journal of Radiation Oncology Biology Physics 2007; 69 (Suppl. 02) DOI: 10.1016/j.ijrobp.2007.04.088.
    CrossrefPubMedGoogle Scholar
  • 36 Pignon JP, le Maître A, Maillard E. et al Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology 2009; 92: 1 . doi:10.1016/j.radonc.2009.04.014
    CrossrefPubMedGoogle Scholar
  • 37 Cohen EEW, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. Journal of Clinical Oncology 2004; 22: 9 . doi:10.1200/JCO.2004.06.147
    PubMedGoogle Scholar
  • 38 Adelstein DJ, Li Y, Adams GL. et al An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. Journal of Clinical Oncology 2003; 21: 1 . doi:10.1200/JCO.2003.01.008
    CrossrefPubMedGoogle Scholar
  • 39 Beckmann GK, Hoppe F, Pfreundner L. et al Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head and Neck 2005; 27: 1 . doi:10.1002/hed.20111
    CrossrefPubMedGoogle Scholar
  • 40 Medina JA, Rueda A, de Pasos AS. et al A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiotherapy and Oncology 2006; 79: 1 . doi:10.1016/j.radonc.2006.03.010
    CrossrefPubMedGoogle Scholar
  • 41 Taylor IVSG, Murthy AK, Vannetzel JM. et al Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. Journal of Clinical Oncology 1994; 12: 2 . doi:10.1200/JCO.1994.12.2.385
    PubMedGoogle Scholar
  • 42 Budach V, Stuschke M, Budach W. et al Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 prospective randomized trial. Journal of Clinical Oncology 2005; 23: 6 . doi:10.1200/JCO.2005.07.010
    CrossrefPubMedGoogle Scholar
  • 43 Bonner JA, Harari PM, Giralt J. et al Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 2010; 11: 1 . doi:10.1016/S1470-2045(09)70311-0
    CrossrefPubMedGoogle Scholar
  • 44 Bourhis J, Sire C, Graff P. et al Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial. The Lancet Oncology 2012; 13: 2 . doi:10.1016/S1470-2045(11)70346-1
    CrossrefPubMedGoogle Scholar
  • 45 Staar S, Rudat V, Stuetzer H. et al Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – Results of a multicentric randomized German trial in advanced head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 2001; 50: 5 . doi:10.1016/S0360-3016(01)01544-9
    CrossrefPubMedGoogle Scholar
  • 46 Garden AS, Harris J, Vokes EE. et al Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. Journal of Clinical Oncology 2004; 22: 14 . doi:10.1200/JCO.2004.12.012
    CrossrefPubMedGoogle Scholar
  • 47 Chougule PB, Akhtar MS, Rathore R. et al Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group phase II study (HN-53). Head and Neck 2008; 30: 3 . doi:10.1002/hed.20700
    CrossrefPubMedGoogle Scholar
  • 48 Haddad R, Sonis S, Posner M. et al Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer 2009; 115: 19 . doi:10.1002/cncr.24525
    CrossrefPubMedGoogle Scholar
  • 49 Suntharalingam M, Kwok Y, Goloubeva O. et al Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. International Journal of Radiation Oncology Biology Physics 2012; 82: 5 . doi:10.1016/j.ijrobp.2011.02.062
    PubMedGoogle Scholar
  • 50 Citrin D, Mansueti J, Likhacheva A. et al Long-Term Outcomes and Toxicity of Concurrent Paclitaxel and Radiotherapy for Locally Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics 2009; 74: 4 . doi:10.1016/j.ijrobp.2008.09.053
    CrossrefPubMedGoogle Scholar
  • 51 Chen AM, Felix C, Wang PC. et al Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. The Lancet Oncology 2017; 18: 6 . doi:10.1016/S1470-2045(17)30246-2
    CrossrefPubMedGoogle Scholar
  • 52 Forastiere AA, Zhang Q, Weber RS. et al Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. Journal of Clinical Oncology 2013; 31: 7 . doi:10.1200/JCO.2012.43.6097
    CrossrefPubMedGoogle Scholar
  • 53 Spreafico A, Huang SH, Xu W. et al Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. European Journal of Cancer 2016; 67 DOI: 10.1016/j.ejca.2016.08.013.
    CrossrefPubMedGoogle Scholar
  • 54 Jacinto KJC, Co J, Mejia MB. et al The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis. British Journal of Radiology 2017; 90: 1079 . doi:10.1259/bjr.20170442
    PubMedGoogle Scholar
  • 55 Bourhis J, Overgaard J, Audry H. et al Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 9538 . doi:10.1016/S0140-6736(06)69121-6
    CrossrefPubMedGoogle Scholar
  • 56 Szturz P, Wouters K, Kiyota N. et al Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis. Oral Oncology 2018; 76 DOI: 10.1016/j.oraloncology.2017.11.025.
    CrossrefPubMedGoogle Scholar
  • 57 Mohamed A, Twardy B, Zordok MA. et al Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Head and Neck 2019; 41: 5 . doi:10.1002/hed.25379
    CrossrefPubMedGoogle Scholar
  • 58 Bauml JM, Vinnakota R, Anna Park YH. et al Cisplatin Every 3 Weeks Versus Weekly with Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute 2019; 111 DOI: 10.1093/jnci/djy133.
    CrossrefPubMedGoogle Scholar
  • 59 Perez CA, Wu X, Amsbaugh MJ. et al High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck. Oral Oncology 2017; 67 DOI: 10.1016/j.oraloncology.2017.01.010.
    CrossrefPubMedGoogle Scholar
  • 60 Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncologica 2008; 47: 8 . doi:10.1080/02841860701846160
    PubMedGoogle Scholar
  • 61 Denis F, Garaud P, Bardet E. et al Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. Journal of Clinical Oncology 2004; 22: 1 . doi:10.1200/JCO.2004.08.021
    CrossrefPubMedGoogle Scholar
  • 62 Guan J, Li Q, Zhang Y. et al A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). Oncotarget 2016; 7: 6 . doi:10.18632/oncotarget.6858
    CrossrefPubMedGoogle Scholar
  • 63 Fietkau R, Hecht M, Hofner B. et al Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. Radiotherapy and Oncology 2020; 144 DOI: 10.1016/j.radonc.2020.01.016.
    CrossrefPubMedGoogle Scholar
  • 64 Furqan M, Snyders TP, Saqlain MU. et al Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC). Cancer Medicine 2019; 8: 6 . doi:10.1002/cam4.2139
    CrossrefPubMedGoogle Scholar
  • 65 Dobrosotskaya IY, Bellile E, Spector ME. et al Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. Head and Neck 2014; 36: 5 . doi:10.1002/hed.23339
    CrossrefPubMedGoogle Scholar
  • 66 ANG KK, Peters LJ, Weber RS. et al Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. International Journal of Radiation Oncology, Biology, Physics 1990; 19: 6 . doi:10.1016/0360-3016(90)90341-G
    PubMedGoogle Scholar
  • 67 Magrini SM, Buglione M, Corvò R. et al Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: A randomized phase II trial. Journal of Clinical Oncology 2016; 34: 5 . doi:10.1200/JCO.2015.63.1671
    CrossrefPubMedGoogle Scholar
  • 68 Ang KK, Harris J, Wheeler R. et al Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. New England Journal of Medicine 2010; 363: 1 . doi:10.1056/nejmoa0912217
    CrossrefPubMedGoogle Scholar
  • 69 Gillison ML, Trotti AM, Harris J. et al Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. The Lancet 2019; 393: 10166 . doi:10.1016/S0140-6736(18)32779-X
    CrossrefPubMedGoogle Scholar
  • 70 Giralt J, Trigo J, Nuyts S. et al Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): A randomised, controlled, open-label phase 2 trial. The Lancet Oncology 2015; 16: 2 . doi:10.1016/S1470-2045(14)71200-8
    CrossrefPubMedGoogle Scholar
  • 71 Lefebvre JL, Pointreau Y, Rolland F. et al Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. Journal of Clinical Oncology 2013; 31: 7 . doi:10.1200/JCO.2012.42.3988
    CrossrefPubMedGoogle Scholar
  • 72 Ang KK, Zhang Q, Rosenthal DI. et al Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. Journal of Clinical Oncology 2014; 32: 27 . doi:10.1200/JCO.2013.53.5633
    PubMedGoogle Scholar
  • 73 Mesía R, Henke M, Fortin A. et al Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): A randomised, controlled, open-label phase 2 trial. The Lancet Oncology 2015; 16: 2 . doi:10.1016/S1470-2045(14)71198-2
    CrossrefPubMedGoogle Scholar
  • 74 Vermorken JB, Remenar E, van Herpen C. et al Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. New England Journal of Medicine 2007; 357: 17 . doi:10.1056/nejmoa071028
    CrossrefPubMedGoogle Scholar
  • 75 Posner MR, Hershock DM, Blajman CR. et al Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. New England Journal of Medicine 2007; 357: 17 . doi:10.1056/nejmoa070956
    CrossrefPubMedGoogle Scholar
  • 76 Haddad R, O’Neill A, Rabinowits G. et al Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. The Lancet Oncology 2013; 14: 3 . doi:10.1016/S1470-2045(13)70011-1
    CrossrefPubMedGoogle Scholar
  • 77 Cohen EEW, Karrison TG, Kocherginsky M. et al Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. Journal of Clinical Oncology 2014; 32: 5 . doi:10.1200/JCO.2013.54.6309
    PubMedGoogle Scholar
  • 78 Geoffrois L, Martin L, de Raucourt D. et al Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial. Journal of Clinical Oncology 2018; 36: 31 . doi:10.1200/JCO.2017.76.2591
    CrossrefPubMedGoogle Scholar
  • 79 Hitt R, Grau JJ, López-Pousa A. et al A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Annals of Oncology 2014; 25: 1 . doi:10.1093/annonc/mdt461
    CrossrefPubMedGoogle Scholar
  • 80 Ghi MG, Paccagnella A, Ferrari D. et al Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Annals of Oncology 2017; 28: 9 . doi:10.1093/annonc/mdx299
    PubMedGoogle Scholar
  • 81 Forastiere AA, Ismaila N, Lewin JS. et al Use of larynx-preservation strategies in the treatment of laryngeal cancer: American society of clinical oncology clinical practice guideline update. Journal of Clinical Oncology 2018; 36: 11 . doi:10.1200/JCO.2017.75.7385
    CrossrefPubMedGoogle Scholar
  • 82 Hassan Metwally MA, Ali R, Kuddu M. et al IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. Radiotherapy and Oncology 2015; 116: 1 . doi:10.1016/j.radonc.2015.04.00
    CrossrefPubMedGoogle Scholar
  • 83 Overgaard J, Hansen HS, Specht L. et al Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet 2003; 362: 9388 . doi:10.1016/S0140-6736(03)14361-9
    CrossrefPubMedGoogle Scholar
  • 84 Overgaard J, Hansen HS, Overgaard M. et al A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology 1998; 46: 2 . doi:10.1016/S0167-8140(97)00220-X
    CrossrefPubMedGoogle Scholar
  • 85 Beitler JJ, Zhang Q, Fu KK. et al Final results of local-regional control and late toxicity of rtog 9003: A randomized trial of altered fractionation radiation for locally advanced head and neck cancer. International Journal of Radiation Oncology Biology Physics 2014; 89: 1 . doi:10.1016/j.ijrobp.2013.12.027
    CrossrefPubMedGoogle Scholar
  • 86 Fu KK, Pajak TF, Trotti A. et al A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. International Journal of Radiation Oncology Biology Physics 2000; 48: 1 . doi:10.1016/S0360-3016(00)00663-5
    PubMedGoogle Scholar
  • 87 Baujat B, Bourhis J, Blanchard P. et al Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database of Systematic Reviews 2010; 2010: 12 . doi:10.1002/14651858.CD002026.pub2
    PubMedGoogle Scholar
  • 88 Lacas B, Bourhis J, Overgaard J. et al Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. The Lancet Oncology 2017; 18: 9 . doi:10.1016/S1470-2045(17)30458-8
    CrossrefPubMedGoogle Scholar
  • 89 Gupta T, Kannan S, Ghosh-Laskar S. et al Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Clinical Oncology 2016; 28: 1 . doi:10.1016/j.clon.2015.09.002
    CrossrefPubMedGoogle Scholar
  • 90 Gupta T, Kannan S, Ghosh-Laskar S. et al Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis. Head and Neck 2015; 37: 5 . doi:10.1002/hed.23661
    CrossrefPubMedGoogle Scholar
  • 91 Nguyen-Tan PF, Zhang Q, Ang KK. et al Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: Long-term report of efficacy and toxicity. Journal of Clinical Oncology 2014; 32: 34 . doi:10.1200/JCO.2014.55.3925
    PubMedGoogle Scholar
  • 92 Saksø M, Jensen K, Andersen M. et al DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity. Radiotherapy and Oncology 2020; 148 DOI: 10.1016/j.radonc.2020.03.025.
    CrossrefPubMedGoogle Scholar
  • 93 Brahme A, Roos JE, Lax I. Solution of an integral equation encountered in rotation therapy. Physics in Medicine and Biology 1982; 27: 10 . doi:10.1088/0031-9155/27/10/002
    CrossrefPubMedGoogle Scholar
  • 94 Münter MW, Karger CP, Hoffner SG. et al Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. International Journal of Radiation Oncology Biology Physics 2004; 58: 1 . doi:10.1016/S0360-3016(03)01437-8
    CrossrefPubMedGoogle Scholar
  • 95 Eisbruch A, ten Haken RK, Kim HM. et al Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. International Journal of Radiation Oncology Biology Physics 1999; 45: 3 . doi:10.1016/S0360-3016(99)00247-3
    PubMedGoogle Scholar
  • 96 Chao KSC, Ozyigit G, Tran BN. et al Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 2003; 55: 2 . doi:10.1016/S0360-3016(02)03940-8
    PubMedGoogle Scholar
  • 97 Lee NY, de Arruda FF, Puri DR. et al A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics 2006; 66: 4 . doi:10.1016/j.ijrobp.2006.06.040
    PubMedGoogle Scholar
  • 98 Setton J, Caria N, Romanyshyn J. et al Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: An update of the memorial sloan-kettering cancer center experience. International Journal of Radiation Oncology Biology Physics 2012; 82: 1 . doi:10.1016/j.ijrobp.2010.10.041
    CrossrefPubMedGoogle Scholar
  • 99 Schoenfeld GO, Amdur RJ, Morris CG. et al Patterns of Failure and Toxicity after Intensity-Modulated Radiotherapy for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics 2008; 71: 2 . doi:10.1016/j.ijrobp.2007.10.010
    CrossrefPubMedGoogle Scholar
  • 100 Cannon DM, Lee NY. Recurrence in Region of Spared Parotid Gland After Definitive Intensity-Modulated Radiotherapy for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics 2008; 70: 3 . doi:10.1016/j.ijrobp.2007.09.018
    CrossrefPubMedGoogle Scholar
  • 101 Feng M, Jabbari S, Lin A. et al Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. Radiotherapy and Oncology 2005; 77: 1 . doi:10.1016/j.radonc.2005.07.008
    CrossrefPubMedGoogle Scholar
  • 102 Nutting CM, Morden JP, Harrington KJ. et al Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. The Lancet Oncology 2011; 12: 2 . doi:10.1016/S1470-2045(10)70290-4
    CrossrefPubMedGoogle Scholar
  • 103 Ghosh-Laskar S, Yathiraj PH, Dutta D. et al Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results. Head and Neck 2016; 38 DOI: 10.1002/hed.24263.
    CrossrefPubMedGoogle Scholar
  • 104 Lin A, Kim HM, Terrell JE. et al Quality of life after parotid-sparing IMRT for head-and-neck cancer: A prospective longitudinal study. International Journal of Radiation Oncology Biology Physics 2003; 57: 1 . doi:10.1016/S0360-3016(03)00361-4
    CrossrefPubMedGoogle Scholar
  • 105 Parliament MB, Scrimger RA, Anderson SG. et al Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 2004; 58: 3 . doi:10.1016/S0360-3016(03)01571-2
    CrossrefPubMedGoogle Scholar
  • 106 Vergeer MR, Doornaert PAH, Rietveld DHF. et al Intensity-Modulated Radiotherapy Reduces Radiation-Induced Morbidity and Improves Health-Related Quality of Life: Results of a Nonrandomized Prospective Study Using a Standardized Follow-Up Program. International Journal of Radiation Oncology Biology Physics 2009; 74: 1 . doi:10.1016/j.ijrobp.2008.07.059
    CrossrefPubMedGoogle Scholar
  • 107 Caglar HB, Tishler RB, Othus M. et al Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics 2008; 72: 4 . doi:10.1016/j.ijrobp.2008.02.048
    CrossrefPubMedGoogle Scholar
  • 108 Caudell JJ, Schaner PE, Meredith RF. et al Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics 2009; 73: 2 . doi:10.1016/j.ijrobp.2008.04.048
    CrossrefPubMedGoogle Scholar
  • 109 Feng FY, Kim HM, Lyden TH. et al Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: Clinical and functional results. Journal of Clinical Oncology 2010; 28: 16 . doi:10.1200/JCO.2009.24.6199
    PubMedGoogle Scholar
  • 110 Feng FY, Kim HM, Lyden TH. et al Intensity-Modulated Radiotherapy of Head and Neck Cancer Aiming to Reduce Dysphagia: Early Dose-Effect Relationships for the Swallowing Structures. International Journal of Radiation Oncology Biology Physics 2007; 68: 5 . doi:10.1016/j.ijrobp.2007.02.049
    PubMedGoogle Scholar
  • 111 Cancer GC (Danish H and NCG. DAHANCA 35 Trial Protocol. DAHANCA 35 Trial Protocol. Accessed July 7, 2020. https://www.dahanca.dk/assets/files/PRO_DAHANCA_35.pdf
    PubMedGoogle Scholar
  • 112 Rwigema JCM, Langendijk JA, Paul van der Laan H. et al A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics 2019; 104: 3 . doi:10.1016/j.ijrobp.2018.12.055
    PubMedGoogle Scholar
  • 113 Langendijk JA, Boersma LJ, Rasch CRN. et al Clinical Trial Strategies to Compare Protons With Photons. Seminars in Radiation Oncology 2018; 28: 2 . doi:10.1016/j.semradonc.2017.11.008
    CrossrefPubMedGoogle Scholar
  • 114 Cramer JD, Ferris RL, Duvvuri U. Treatment deintensification to surgery only for stage I human papillomavirus-associated oropharyngeal cancer. Journal of Clinical Oncology 2018; 36 (Suppl. 15) DOI: 10.1200/jco.2018.36.15_suppl.6003.
    CrossrefPubMedGoogle Scholar
  • 115 Mehanna H, Robinson M, Hartley A. et al Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. The Lancet 2019; 393: 10166 . doi:10.1016/S0140-6736(18)32752-1
    CrossrefPubMedGoogle Scholar
  • 116 Chera BS, Amdur RJ, Tepper J. et al Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics 2015; 93: 5 . doi:10.1016/j.ijrobp.2015.08.033
    CrossrefPubMedGoogle Scholar
  • 117 Uppaluri R, Zolkind P, Lin T. et al Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology 2017; 35 (Suppl. 15) DOI: 10.1200/jco.2017.35.15_suppl.6012.
    CrossrefPubMedGoogle Scholar
  • 118 Wise-Draper TM, Old MO, Worden FP. et al Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. Journal of Clinical Oncology 2018; 36 (Suppl. 15) DOI: 10.1200/jco.2018.36.15_suppl.6017.
    CrossrefPubMedGoogle Scholar